Follicular lymphoma natural history, complications and prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Overview
Follicular lymphoma presents in the age group of 60-65 with systemic symptoms of fever, weight loss, anorexia, night sweats and other organ dependent symptoms based on the metastatic spread of the lymphoma. Complications arise from the systemic effects of the lymphoma and metastasis. The prognosis is evaluated from follicular lymphoma international prognostic index which divides patients into 3 groups.
Natural history
Natural history
- Follicular lymphoma presents in older age group people of age 60-65[1][2][3][4].
- Patients may present with complaints of:
- Unexplained fever
- Weight loss
- Painless and progressive adenopathy
- Night sweats
- Nerve lesions
- Constant fatigue
- Itchy skin
- Reddened patches on the skin
- Cough
- Shortness of breath
- Organ-related symptoms develop depending on the metastatic spread of the lymphoma.
- Patients may have a history of:
- Viral disease (HIV, HBV, HCV or EBV)
- Autoimmune diseases
- Immunocompromised state
Complications
Complications
- Skin reactions
- Bone marrow suppression
- Secondary cancers
- Gastric obstruction
- Urethral obstruction
- Renal failure
- Infertility
- Heart disease (Heart failure, valvular defects, pericarditis)
- Lung disease (Pleural effusion, lung mass)
- Mediastinal mass
- Immune system deficiency
Prognosis
Prognosis
- Follicular Lymphoma International Prognostic Index (FLIPI) is used for the evaluation of prognosis.[5][6]
- It includes the following:
- Age >60 years
- Bone marrow involvement
- Hemoglobin level <12.0 g/dl
- Greatest diameter of the largest involved node >6 cm
- Elevated serum β-2 microglobulin level
- The FLIPI divides patients into 3 groups:
- Low (0-1 risk factor)
- Intermediate (2 risk factors)
- High (≥ 3 risk factors)
- The 10-year mortality of low group is 96%.
- The 10-year mortality of intermediate group is 71%.
- The 10-year mortality of high group is 37%.
References
References
- ↑ Kridel R, Sehn LH, Gascoyne RD (2012). “Pathogenesis of follicular lymphoma”. J Clin Invest. 122 (10): 3424–31. doi:10.1172/JCI63186. PMC 3461914. PMID 23023713.
- ↑ “A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project”. Blood. 89 (11): 3909–18. 1997. PMID 9166827.
- ↑ Winberg CD, Nathwani BN, Bearman RM, Rappaport H (1981). “Follicular (nodular) lymphoma during the first two decades of life: a clinicopathologic study of 12 patients”. Cancer. 48 (10): 2223–35. PMID 7028244.
- ↑ Fernández de Larrea C, Martínez-Pozo A, Mercadal S, García A, Gutierrez-García G, Valera A; et al. (2011). “Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma”. Br J Haematol. 153 (3): 334–40. doi:10.1111/j.1365-2141.2011.08596.x. PMID 21375524.
- ↑ Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R; et al. (2004). “Follicular lymphoma international prognostic index”. Blood. 104 (5): 1258–65. doi:10.1182/blood-2003-12-4434. PMID 15126323.
- ↑ Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM; et al. (1995). “Prognostic value of cellular proliferation and histologic grade in follicular lymphoma”. Blood. 85 (12): 3671–8. PMID 7780151.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
